Evaluation of Dimebon in Huntington's Disease
Author Information
Author(s): Wu Jun, Li Qin, Bezprozvanny Ilya
Primary Institution: UT Southwestern Medical Center
Hypothesis
Can Dimebon inhibit NMDA receptors and voltage-gated calcium channels in a cellular model of Huntington's disease?
Conclusion
Dimebon shows potential neuroprotective effects in Huntington's disease by stabilizing calcium signaling and inhibiting NMDA receptors.
Supporting Evidence
- Dimebon inhibited NMDA receptors with an IC50 of 10 μM.
- Dimebon stabilized glutamate-induced calcium signals in YAC128 MSN at 50 μM.
- At 50 μM, Dimebon showed significant protective effects against glutamate-induced apoptosis.
Takeaway
Dimebon might help protect brain cells in Huntington's disease by keeping calcium levels stable and blocking certain brain signals.
Methodology
The study involved primary striatal neuronal cultures from wild type and YAC128 HD transgenic mice, assessing the effects of Dimebon on NMDA receptors and calcium channels.
Potential Biases
Potential interactions with various receptors could influence the interpretation of results.
Limitations
The concentrations of Dimebon required for neuroprotective effects may not be achievable in human trials.
Participant Demographics
The study involved male YAC128 mice and wild type mice.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website